This repository is under review for potential modification in compliance with Administration directives.
The AMP PD Knowledge Portal was developed to host and share resources related to Parkinson’s disease research and remains fully operational. We continue to maintain and accept Parkinson’s disease and related disorders data and resources throughout this review process.

AMP EXECUTIVE COMMITTEE (EC)

The AMP® EC is responsible for the overall AMP® program and oversees the steering committees of each AMP disease-specific project. This governance structure allows the program to remain abreast of the ever-evolving science. The AMP EC is responsible for approving new AMP projects and reviewing the progress and milestone achievement of ongoing projects and enables feedback and cross-learning between projects across therapeutic areas. AMP EC meetings are usually held in a closed forum with additional experts invited to participate according to the needs of the EC.

The EC includes leaders from NIH, FDA, and Private Industry/ Non-Profit/Patient Advocacy Co-Chairs from AMP project Steering Committees. The EC convenes quarterly with EC liaison representatives, NIH Office of the Director (OD) liaison representatives, and co-chairs from each of the AMP Project Steering Committees represented on the EC. The AMP PDRD steering committee EC Liaison is Walter Koroshetz, M.D., Director of NINDS. 

The Co-Chairs of the AMP PDRD Steering Committee are:

  • Christine Swanson-Fischer, Director, Program Director Division of Neuroscience Movement Disorders and Neurodegeneration Cluster, NINDS
  • Stacy Henry, Senior Director, Denali Therapeutics
  • Mark Frasier, Chief Scientific Officer, The Michael J. Fox Foundation 

AMP EXTENDED EXECUTIVE COMMITTEE (EEC)

The AMP EEC meets twice a year and includes the EC members as well as additional private partner representatives from AMP Project Steering Committees (or a proxy representative) to participate in discussions of the latest scientific advancements and the progress of ongoing AMP projects and encourages broad interaction and exchange of ideas among the AMP community.

AMP PDRD Steering Committee

Goal: The AMP® PDRD Steering Committee (SC) will operate under the direction of the AMP Executive Committee (EC) and is responsible for defining and maintaining the research plan for the AMP® PDRD Project, for review of progress of the AMP® PDRD Project, and for the detailed assessment of milestones. The AMP® PDRD Steering Committee provides strong but flexible joint management of the initiative over the five-year implementation of the Research Plan. It allows the partners a mechanism to closely follow the science and changes in the field for the duration of the partnership and to ensure effective results and timely use of resources and assess its progress.

The AMP PDRD SC is organized by FNIH and is comprised of representatives from the private sector organizations that fund the partnership as well as members from government (NINDS, NIA, and FDA). FNIH serves as the non-voting Executive Secretary of the SC and will facilitate the development of meeting agendas and materials under the guidance of the SC Co-Chairs in consultation with the NINDS program officials.

The AMP® PDRD SC is co-chaired by one representative from the NINDS and two members (Industry & Non-Profit) from the AMP® PDRD private sector partner organizations nominated by the SC. The SC may elect to include additional key outside (non-voting) experts to provide appropriate domain expertise relevant to the research topics.

The AMP® PDRD SC has representatives from all AMP® PDRD government partners (NINDS, NIA,  FDA), industry partners (C2N Diagnostics, Denali Therapeutics, GlaxoSmithKline, Labcorp, Sanofi, and Verily) and the non-profit partners (Aligning Science Across Parkinson’s [ASAP] Initiative and The Michael J. Fox Foundation for Parkinson’s Research [MJFF]).

Additionally, AMP® PDRD values patient engagement as a fundamental core of the program to incorporate patient perspectives and expertise as part of the AMP PDRD program. The AMP® PDRD patient advocacy SC representatives are Soania Mathur and Kevin Kwok.

Roster

Steering Committee Co-Chairs

  • Stacy Henry, Ph.D. (Denali Therapeutics)
  • Mark Frasier, Ph.D. (MJFF)
  • Christine Swanson-Fischer, Ph.D. (NIH/NINDS)

Executive Committee Liaison

  • Walter Koroshetz, M.D. (NIH/NINDS)

NIH/OD Liaison

  • Walter Koroshetz, M.D. (NIH/NINDS)

Public Partner Representatives

  • Teresa Buracchio, M.D. (FDA)
  • Gerald (Dave) Podskalny, D.O., M.P.H. (FDA)
  • Debra Babcock, M.D., Ph.D. (NIH/NINDS)
  • Patrick Bellgowan, Ph.D. (NIH/NINDS)
  • Lauren Laboissonniere, Ph.D. (NIH/NINDS)

Private/ Non-Profit Partner Representatives

  • Cornelis Blauwendraat, Ph.D. (ASAP)
  • Sonya Dumanis, Ph.D. (ASAP)
  • Philip Verghese, Ph.D. (C2N)
  • Sutapa Ray, Ph.D. (C2N)
  • Anastasia Henry, Ph.D. (Denali Therapeutics)
  • Joseph Lewcock, Ph.D (Denali Therapeutics)
  • Guhan Nagappan, Ph.D. (GSK)
  • Nazneen Barwick, Ph.D. (GSK)
  • Prerak Desai, Ph.D. (GSK)
  • John Winslow, Ph.D. (Labcorp)
  • Robert Martone, B.S. (Labcorp)
  • Justin Solle, MBA (MJFF)
  • Pablo Sardi, Pharm.D., Ph.D. (Sanofi)
  • Rajaraman Krishnan, Ph.D. (Sanofi)
  • Matt Bookman, M.S. (Verily)
  • Willy Nojopranoto, B.S. (Verily)

Patient Advocacy Representatives

  • Kevin Kwok, Pharm.D.
  • Soania Mathur, M.D. 

Ex-Officio Managing Partner

  • Tyler Fortuna, Ph.D. (FNIH)
  • Christi Anne Ng, B.S. (FNIH)
  • Sri Pullagura, Ph.D. (FNIH)
  • Alessio Travaglia, Ph.D., P.M.P (FNIH)

AMP PDRD Data Operations Service Provider

  • Barry Landin, B.S. (Technome)

AMP PDRD Biomarkers Working Group

Goal: Identify and validate a panel of potential biomarker candidates and assay platforms for PD and Related Disorders to inform patient stratification, monitor disease progression, enable clinical trial design, and accelerate development of meaningful therapies for PDRD patients.

Roster

Working Group Co-Chairs

  • Carol Taylor-Burds (NIH/NINDS)
  • Jillian Kluss (Denali Therapeutics)

Public Partner Representatives

  • Gerald (Dave) Podskalny (FDA)
  • Kevin Krudys (FDA)
  • Natasha Thorne (FDA)
  • Sreedharan Sabarinath (FDA)
  • Christine Swanson-Fischer (NIH/NINDS)
  • Lauren Laboissonniere (NIH/NINDS)

Private/ Non-Profit Partner Representatives

  • Sutapa Ray (C2N)
  • Daniel Fleck (Denali Therapeutics)
  • Jung Suh (Denali Therapeutics)
  • Sarah Huntwork-Rodriguez (Denali Therapeutics)
  • Shan Andrews (Denali Therapeutics)
  • Stacy Henry (Denali Therapeutics)
  • Charity Atkins (GSK)
  • Dean McNulty (GSK)
  • Rianne Esquivel (GSK)
  • Sue Ng (GSK)
  • Christos Petropoulos (Labcorp)
  • John Winslow (Labcorp)
  • Joseph Volpe (Labcorp)
  • Robert Martone (Labcorp)
  • Samantha Hutten (MJFF)
  • Adriana Ramos (Sanofi)
  • Lilu Guo (Sanofi)

Patient Advocacy Representatives

  • Kevin Kwok
  • Soania Mathur

Ex-Officio Managing Partner

  • Tyler Fortuna (FNIH)
  • Christi Anne Ng (FNIH)
  • Sri Pullagura (FNIH)

AMP PDRD Data Operations Service Provider

  • Victoria Dardov (Technome)

AMP PDRD Outreach Working Group

Goal: Develop outreach efforts for the program aimed at driving awareness to the public about the AMP PDRD Knowledge Portal and AMP PDRD program.

Roster

Working Group Co-Chairs

  • Christine Swanson-Fischer (NIH/NINDS)

Public Partner Representatives

  • Lauren Laboissonniere (NIH/NINDS)
  • Natalia Volfovsky (NIH/NINDS)

Private/ Non-Profit Partner Representatives

  • Devin Snyder (ASAP)
  • Jennifer Brummet (CurePSP)
  • Sabrina Da Rocha (CurePSP)
  • Ryan Patrick (Labcorp)
  • David Kumbroch (MJFF)
  • John Wilson (Verily)

Patient Advocacy Representatives

  • Soania Mathur
  • Kevin Kwok 

Ex-Officio Managing Partner

  • Tyler Fortuna (FNIH)
  • Sri Pullagura (FNIH)
  • Christi Anne Ng (FNIH)
     

AMP PDRD Cohort Expansion Working Group

Goal: Advance PDRD cohort expansion efforts related to biomarker evaluation and multi-omic profiling through the identification and onboarding of genetic PD, prodromal PD, and other α-synucleinopathy cohorts. Additionally, aim to introduce shared data access approaches with other neuro data consortiums of interest.  

Roster

Working Group Co-Chairs

  • Christine Swanson-Fischer (NIH/NINDS)
  • Rajaraman Krishnan (Sanofi)

Public Partner Representatives

  • Kevin Krudys (FDA)
  • Natalia Volfovsky (NIH/NINDS)
  • Lauren Laboissonniere (NIH/NINDS)

Private/ Non-Profit Partner Representatives

  • Cornelis Blauwendraat (ASAP)
  • Stacy Henry (Denali Therapeutics)
  • Jillian Kluss (Denali Therapeutics)
  • Danna Jennings (Denali Therapeutics)
  • Nazneen Barwick (GSK)
  • Stephanie Benvengo (MJFF)
  • Willy Nojopranoto (Verily) 

Ex-Officio Managing Partner

  • Tyler Fortuna (FNIH)
  • Sri Pullagura (FNIH)
  • Christi Anne Ng (FNIH)

AMP PDRD Data Operations Service Provider

  • David Vismer (Technome) 

AMP PD STEERING COMMITTEE (SC)

The AMP PD Steering Committee (SC) will operate under the direction of the AMP Executive Committee (EC) and is responsible for defining and maintaining the research plan for the AMP PD Project, for review of progress of the AMP PD Project, and for the detailed assessment of milestones. The AMP PD Steering Committee provides strong but flexible joint management of the initiative over the five-year implementation of the Research Plan. It allows the partners a mechanism to closely follow the science and the changes in the field for the duration of the partnership, in order to ensure effective results and timely use of resources and assess its progress.

The AMP PD SC is organized by FNIH and is comprised of representatives from the private sector organizations that fund the partnership as well as members from government (NINDS, NIA and FDA). FNIH serves as the non-voting Executive Secretary of the SC and will facilitate the development of meeting agendas and materials under the guidance of the SC Co-Chairs in consultation with the NINDS program officials.

The AMP PD SC is co-chaired by one representative from the NINDS and one member from the AMP PD private sector partners nominated by the SC. The SC may elect to include additional key outside (but non-voting) experts to provide appropriate domain expertise relevant to the research topics. 

The AMP PD SCS has representatives from all AMP PD government partners (NIA, NINDS, FDA), industry partners (AbbVie, Celgene subsidiary of Bristol-Myers Squibb Company, GlaxoSmithKline, Pfizer, Sanofi, and Verily) and the non-profit partners (Aligning Science Across Parkinson’s (ASAP) Initiative and The Michael J. Fox Foundation for Parkinson’s Research).

AMP PD Steering Committee, as of October 2022

Co-chairs

  • Debra Babcock, Ph.D., M.D. (NIH/NINDS)
    National Institutes of Health
  • Pablo Sardi, Ph.D., Pharm. D.
    Sanofi US Services Inc.

Executive Committee Liaison

  • Walter Koroshetz, M.D.
    National Institutes of Health

NIH/OD Liaison

  • Ellen Gadbois, Ph.D.
    National Institutes of Health

Public Partner Representatives

  • Billy Dunn, M.D.,
    U.S. Food and Drug Administration
  • Gerald Podskalny, D.O.
    U.S. Food and Drug Administration
  • Lyn Jakeman, Ph.D., B.A.
    National Institutes of Health
  • Patrick Bellgowan, Ph.D.
    National Institutes of Health
  • Suzana Petanceska, Ph.D., B.S.
    National Institutes of Health

Private Funding Partner Representatives

  • David Glazer, S.B.,
    Verily Life Sciences
  • Ekemini Riley, Ph.D., B.A.
    Aligning Science Across Parkinson’s (ASAP) Initiative
  • Guhan Nagapan, Ph.D.
    GlaxoSmithKline
  • Gopi Ganji, Ph.D.
    GlaxoSmithKline
  • Irit Rapley, Ph.D., B.S.
    Celgene subsidiary of Bristol-Myers Squibb Company
  • Leslie Shinobu, M.D., Ph.D. 
    Celgene subsidiary of Bristol-Myers Squibb Company
  • Robert Moccia, M.D., Ph.D.
    Pfizer Inc.
  • Shameek Biswas, Ph.D., M.Eng.
    Celgene subsidiary of Bristol-Myers Squibb Company
  • Todd Sherer, Ph.D., B.S.
    The Michael J. Fox Foundation for Parkinson's Research
  • William Marks, Jr., M.D., M.S.
    Verily Life Sciences
  • Jan Stoehr, Ph.D.,
    AbbVie

Managing Partners

  • Stacey Adam, Ph.D
    Foundation for the National Institutes of Health

Adhoc Guests

  • Richard Hargreaves, Ph.D., B.S.
    Celgene subsidiary of Bristol-Myers Squibb Company

WORKING GROUPS & SUBGROUPS

AMP PD Working Groups and Subgroups are created under the direction of the AMP PD Steering Committee to provide detailed technical guidance for key scientific, policy or informatics issues that arise during implementation of the Research Plan. These Working Subgroups are created and sunsetted based on need, and will operate under one main working group umbrella, the AMP PD Data Working Group or AMP PD Data Analyses Working Group. Like the Steering Committee, the Working Groups and Subgroups will be supported and staffed by an FNIH Program or Project Manager.
At initiation of the working group and subgroups, representatives elected will be invited to a kickoff meeting where the goals of AMP PD and of the specific group are described and discussed. Working group members are invited to nominate those within the working group to public and private co-chair positions.

Working group members are also asked to consider if the relevant expertise is available in the group and if outside expertise is required to drive forward a considered approach. If outside expertise is required, the AMP PD SC is informed of the recommendation. Outside experts are required to share any conflicts of interest with the working group, are recused from final decision making, and may be recused from discussions where they may have conflicts.

The Working Groups and Subgroups focus on specific building blocks required to develop the AMP PD Knowledge Portal with emphasis on data, outreach, policy, and infrastructure.

Of note, the Principal Investigators (PIs) of cohorts contributing data are also invited to have a representative attend working groups relevant to their data contributions. 

Data Analysis Working Group

The Data Analysis Working Group (i) identifies the scientific questions AMP PD would like to address as a consortium; (ii) Defines analyses, tool, and publication priorities; (iii) Reviews publication process and proposals; (iv) Reviews criteria for adding tools to the AMP PD Knowledge Platform.

AMP PD Data Analysis Working Group, as of November 1, 2022

  • Bradford Casey (MJFF) – Co-Chair
  • David Craig (USC) – Co-Chair
  • Alyssa Reimer (MJFF)
  • Andrew Sharp (MSSM)
  • Andy Singleton (NIA/LNG)
  • Christoph Bussler (Verily)
  • Clemens Scherzer (BWH)
  • David Alonso (MJFF)
  • Hirotaka Iwaki (DataTecnica/NIA)
  • David Knowles (NYGenome)
  • David Vismer (FNIH Contractor)
  • Debra Babcock (NINDS)
  • Stacey Adam (FNIH)
  • Elizabeth Hutchins (TGEN)
  • Erin Teeple (Sanofi US Services Inc.)
  • Hampton Leonard (DataTecnica/NIA)
  • Hirotaka Iwaki (DataTecnica/NIA)
  • Ivo Violich (USC)
  • Jie Yuan (BWH)
  • Leslie Kirsch (MJFF)
  • Kendall Van Keuren-Jensen (TGEN)
  • Manisha Brahmachary (Sanofi US Services Inc.)
  • Mary Makarious (NIA/NINDS)
  • Matt Bookman (Verily)
  • Meaghan Cogswell (Sanofi US Services Inc.)
  • Mike Nalls (DataTecnica/NIA)
  • Ramsey Magana (GSK)
  • Ramiya Sivakumar (USC)
  • Ricardo Vialle (MSSM)
  • Rob Woodruff (GSK)
  • Ruifeng Hu  (BWH)
  • Samantha Hutten (MJFF)
  • Shameek Biswas (BMS)
  • Srini Shankara (Sanofi US Services Inc.)
  • Towfique Raj (MSSM)
  • Xianjun Dong (BWH)

Data Use and Policies Working Group

The Data Use Policies Subgroup works together with the Steering Committee to create AMP PD Governance Documents and works with the other Subgroups to ensure policies are implemented.

AMP PD Data Use and Policies Working Group, as of November 1, 2022

  • Open Private Sector – Co-Chair
  • Debra Babcock (NINDS) – Co-Chair
  • Caroline Pentazis (NINDS)
  • Claire Wegel (IU/GP2)
  • Clemens Scherzer (BWH)
  • Ekemini Riley (ASAP)
  • Stacey Adam (FNIH)
  • Justin Solle (MJFF – GP2)
  • Leslie Kirsch (MJFF)
  • Sonja Scholz (NIA – LBD)
  • Dave Alonso (MJFF – LCC)

Data Working Group

The Data Working Group is made up of other working groups that are part of AMP PD. This WG helps align all other working groups, provides continuity and ultimately makes data related recommendations to the Steering Committee. This, in function, has be partly been replaced by the Data Analyses Working Group as the focus of the program has shifted partially from data generation to data analyses.

AMP PD Data Working Group, as of December 18, 2021

  • Debra Babcock (NINDS) – Co-Chair
  • Matt Bookman (Verily) – Co-Chair
  • Alyssa Reimer (MJFF)
  • Andy Singleton (NIA/LNG)
  • Arthur Toga (USC)
  • Bailin Zhang (Sanofi)
  • Barry Landin (FNIH Contractor)
  • Bradford Casey (MJFF)
  • Codrin Lungu (NINDS)
  • David Craig (USC)
  • Dinesh Kumar (Sanofi)
  • Dongyu Liu (Sanofi)  
  • Eline Appelmans (FNIH)
  • Erin Teeple (Sanofi)
  • Jackie Ward (NIH)
  • Juan Botia (KCL)
  • Lungu Codrin (NINDS)
  • Mike Nalls (NIA, LNG)
  • Pablo Sardi (Sanofi)
  • Ritu Kapur (Verily)
  • Robert Moccia (Pfizer)
  • Shameek Biswas (Celgene/BMS)
  • Willy Nojopranoto (Verily)

Umbrella Data Working Group – Sunsetted and replaced by Data Analyses Working Group

  • Debra Babcock (NINDS) – Co-Chair
  • Matt Bookman (Verily) – Co-Chair
  • Alyssa Reimer (MJFF)
  • Andy Singleton (NIA/LNG)
  • Arthur Toga (USC)
  • Bailin Zhang (Sanofi US Services Inc.)
  • Barry Landin (FNIH Contractor)
  • Bradford Casey (MJFF)
  • Codrin Lungu (NINDS)
  • David Craig (USC)
  • Eline Appelmans (FNIH)
  • Erin Teeple (Sanofi US Services Inc.)
  • Juan Botia (KCL)
  • Lungu Codrin (NINDS)
  • Mike Nalls (NIA, LNG)
  • Pablo Sardi (Sanofi US Services Inc.)
  • Ritu Kapur (Verily)
  • Robert Moccia (Pfizer Inc.)
  • Shameek Biswas (BMS)
  • Willy Nojopranoto (Verily)

Outreach and Portal Subgroup

The Outreach portion of this Subgroup will create and AMP PD outreach strategy by defining audiences for targeted outreach efforts, defining outreach priorities, identifying activities, selecting forums to carry out activities, and creating timeline for implementation of a activities
The Portal portion of this Subgroup will create infrastructure and content that is tailored to meet the needs of the AMP PD Portal’s target audiences.

AMP PD Outreach and Portal Subgroup, as of December 18, 2021

  • Patrick Bellgowan (NINDS) – Co-Chair
  • Leslie Kirsch (MJFF) – Co-Chair
  • Carl Wonders (NINDS)
  • Chris Swanson-Fischer (NINDS)
  • David Alonso (MJFF)
  • Debra Babcock (NINDS)
  • Stacey Adam (FNIH)
  • Sam Mooney (FNIH)
  • Kristine Treece (Sapient/NINDS contractor)
  • Sumit Dey (QMUL/GP2)
  • Barbara Marebwa (MJFF)
  • Erin Bryant (NINDS)
  • Barry Landin (Technome/FNIH Contractor)
  • Katherine Thompson (FNIH)

Ad-hoc

  • Barbara Marebwa (MJFF)
  • Amy Adams (NINDS)
  • Barry Landin (FNIH Contractor)
  • Katherine Thompson (FNIH)
  • Suzanne Beschamps (FNIH)
  • Ryan Stewart-Frederick (FNIH Contractor)

Proteomics Subgroup

The main aim of the Proteomics Subgroup is to develop untargeted and targeted Proteomics data that can be easily accessed and used by researchers to interrogate genes, pathways, and mechanisms that may play a role in disease.

AMP PD Proteomics Subgroup, as of October 2022

  • Debra Babcock (NINDS) – Co-Chair
  • Samantha Hutten (MJFF) – Co-Chair
  • Amilcar Flores-Morales (Sanofi US Services Inc.)
  • Andy Christoforou (BMS)
  • Bailin Zhang (Sanofi US Services Inc.)
  • Barry Landin (Technome/FNIH Contractor)
  • Bradford Casey (MJFF)
  • Christine Swanson-Fischer (NINDS)
  • Stacey Adam (FNIH)
  • Howard Schulman (KOL)
  • Lin An (Sanofi US Services Inc.)
  • Lyn Jakeman (NINDS)
  • Marcus Bantscheff (GSK)
  • Mark Frasier (MJFF)
  • Pablo Sardi (Sanofi US Services Inc.)
  • Aparna Vasanthakumar (AbbVie)

Transcriptomics and Whole Genome Sequencing Subgroup

The main aim of the Transcriptomics portion of this subgroup is to develop a comprehensive RNA resource from whole blood samples that can be easily accessed and used by researchers to interrogate genes, pathways, and mechanisms that may play a role in disease. The overall aims of the whole genome sequencing component of this subgroup are to generate large-scale genetic data, develop and adopt standardized processing and quality control protocols, present the data in a framework that enables browsing and analysis, and integrate the data with all other AMP PD data types.

AMP PD Transcriptomics and Whole Genome Sequencing Subgroup, as of December 18, 2021

  • Andy Singleton (NIA/LNG) – WGS Co-Chair
  • Shameek Biswas (BMS) – WGS Co-Chair
  • Kendall Jensen (TGen) – Co-chair
  • Debra Babcock (NINDS) – Co-Chair (Temp)
  • Barry Landin (FNIH Contractor)
  • Bradford Casey (MJFF)
  • Christine Swanson-Fischer (NINDS)
  • Christoph Bussler (Verily)
  • Daniel Seaton (GSK)
  • David Craig (USC)
  • David Pulford (GSK)
  • David Vismer (FNIH Contractor)
  • Dena Hernandez (NIA)
  • Eline Appelmans (FNIH)
  • Elizabeth Hutchins (TGen)
  • Guhan Nagappan (GSK)
  • Hampton Leonard (NIA)
  • Hirotaka Iwaki (NIA)
  • Ivo Violich (USC)
  • Jie Yuan (BWH)
  • Lyn Jakeman (NINDS)
  • Mark Frasier (MJFF)
  • Mary Makarious (NIA/NINDS)
  • Matt Bookman (Verily)
  • Meaghan Cogswell (Sanofi US Services Inc.)
  • Mike Nalls (NIA)
  • Ramsey Magana (GSK)
  • Robert Moccia (Pfizer Inc.)
  • Robert Woodruff (GSK)
  • Ruifeng Hu (BWH)
  • Shawn Levy (Hudson Alpha)
  • Sonja Scholz (NIA)
  • Srini Shankara (Sanofi US Services Inc.)
  • Willy Nojopranoto (Verily)
  • Xianjun Dong (BWH)

Data Generation and Harmonization Working Group

The function of this working group is to ensure the quality of clinical and omics data generated for the AMP PD platform. This working group is a merge of the Data Working Group, Metabolomics subgroup, Transcriptomics and Whole Genome Sequencing Subgroup, and Single Cell RNA Sequencing in the Brain Subgroup.

AMP PD Data Generation and Harmonization Subgroup, as of November 29, 2022

  • Erin Teeple (Sanofi US Services, Inc.) – Co-Chair
  • Debra Babcock (NINDS) – Co-Chair
  • Barry Landin (Technome/FNIH Contractor)
  • Christoph Blohmke (GSK)
  • Clemens Scherzer (BWH)
  • David Pulford (GSK)
  • David Vismer (Technome/FNIH Contractor)
  • Stacey Adam (FNIH)
  • Mary Makarious (NIA)
  • Nicole Glazer (BMS)
  • Robert Moccia (Pfizer Inc.)
  • Bradford Casey (MJFF)
  • Charissa Dwyer (GSK)
  • David Craig (USC)
  • Suzana Petanceska (NIA)
  • Qin An (GSK)
  • Andy Singleton (NIA/LNG)
  • Shameek Biswas (BMS)
  • Kendall Van Keuren-Jensen (TGen)
  • Christine Swanson-Fischer (NINDS)
  • Christoph Bussler (Verily)
  • Dena Hernandez (NIA)
  • Elizabeth Hutchins (TGen)
  • Guhan Nagappan (GSK)
  • Hampton Leonard (NIA)
  • Hirotaka Iwaki (NIA)
  • Ivo Violich (USC)
  • Jie Yuan (BWH)
  • Lyn Jakeman (NINDS)
  • Mark Frasier (MJFF)
  • Matt Bookman (Verily)
  • Meaghan Cogswell (Sanofi US Services Inc.)
  • Mike Nalls (DataTecnica/NIA)
  • Ramsey Magana (GSK)
  • Robert Moccia (Pfizer Inc.)
  • Robert Woodruff (GSK)
  • Ruifeng Hu (BWH)
  • Sonja Scholz (NINDS)
  • Srini Shankara (Sanofi US Services Inc.)
  • Willy Nojopranoto (Verily)
  • Xianjun Dong (BWH)
     

With thanks to former AMP PD working group members

  • Amy Adams (NINDS)
  • Eline Appelmans (FNIH)
  • Suzanne Beschamps (FNIH)
  • Shawn Levy (HudsonAlpha)
  • Codrin Lungu (NINDS)
  • Ryan Stewart-Frederick (FNIH Contractor)